ADWX 1

ADWX 1 is a new peptide inhibitor that is potent and selective for Kv1.3 with an IC₅₀ value of 1.89 pM. ADWX 1 inhibits Kv1.3 channel activity specifically to inhibit both the initial calcium signaling and NF-κB activation. ADWX 1 ameliorates the disease in rats of experimental autoimmune encephalomyelitis (EAE) models. ADWX 1 can be used to study T cell-mediated autoimmune diseases^[1][2]. In Vitro: ADWX 1 (1,10 nM, 1 h) inhibits IL-2 and IFN-γ productions, and inhibits humans CD4⁺ CCR7^- T_EM cells activation selectively^[2].
ADWX 1 (1,10 nM, 50 min) reduces [Ca²⁺] in activated CD4⁺ CCR7^- T_CM cells from EAE rats^[2].
ADWX 1 (1,10 nM, 1 h) reduces NF-κB activation and suppresses Kv1.3 expression at both mRNA and protein levels preferentially in myelin basic protein (MBP) (HY-P77995)-stimulated CD4⁺ CCR7^- T cells from EAE rats^[2].
ADWX 1 (1,10 nM, 3 days) suppresses Th17 activation but not differentiation in CD4⁺ CCR7^- T cells^[2].
In Vivo: ADWX 1 (100 μg/kg/day, s.c., 3 days) ameliorates the disease through the inhibition of IL-2 and IFN-γ productions and CCR7^- T_EM proliferation in experimental autoimmune encephalomyelitis (EAE) of Sprague-Dawley rats^[2].
ADWX 1 (5/10 mg/kg, s.c., 2 weeks) induces no pathological changes in the behavior or tissues of the rats (acute toxicity assay)^[2].